Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate ICP-488.Efficacy, safety, PK, and PD characteristics in Chinese adults with moderate to severe plaque psoriasis.

Timeline

Start

2024-01-04

Primary completion

2024-08-05

Completion

2024-09-18

Outcome

Met primary endpoint

release “ICP-488治疗中重度斑块状银屑病II期临床研究达到主要终点” innocarepharma.com ↗

Drugs

Indications